Thus, Runx2 and Runx3 might act as tumour suppressors in malignant melanoma (Martinez et al, 2005), and Runx3 in breast, gastric, colon, and hepatocellular carcinomas, as well as non-small cell lung cancer (Goel et al, 2004; Sakakura et al, 2005; Lau et al, 2006; Miyagawa et al, 2006; Yanagawa et al, 2007). Here, RUNX3 is linked to melanoma.